Nuvilex Inc. (NASDAQ:PMCB) Short Interest Update

by · The Markets Daily

Nuvilex Inc. (NASDAQ:PMCB – Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 106,373 shares, a decrease of 24.4% from the February 12th total of 140,630 shares. Based on an average daily trading volume, of 100,244 shares, the short-interest ratio is currently 1.1 days. Approximately 1.1% of the company’s shares are short sold. Approximately 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 100,244 shares, the short-interest ratio is currently 1.1 days.

Insider Activity

In related news, CEO Joshua Silverman acquired 40,000 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were purchased at an average price of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the acquisition, the chief executive officer owned 416,250 shares in the company, valued at approximately $345,487.50. This represents a 10.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders bought 110,000 shares of company stock worth $89,000 over the last quarter. 10.33% of the stock is currently owned by company insiders.

Nuvilex Price Performance

Nuvilex stock traded down $0.00 during trading hours on Friday, reaching $0.69. The stock had a trading volume of 30,151 shares, compared to its average volume of 105,951. The company has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $0.87. Nuvilex has a 52 week low of $0.63 and a 52 week high of $1.73. The stock has a market cap of $7.41 million, a PE ratio of -0.50 and a beta of 0.33.

Nuvilex (NASDAQ:PMCB – Get Free Report) last issued its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PMCB shares. Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Thursday, January 22nd. Wall Street Zen upgraded Nuvilex to a “sell” rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

View Our Latest Analysis on Nuvilex

Nuvilex Company Profile

(Get Free Report)

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.

See Also